Arsenic trioxide preferentially binds to the ring finger protein PML: understanding target selection of the drug
Metallomics2018Vol. 10(11), pp. 1564–1569
Citations Over TimeTop 22% of 2018 papers
Abstract
Arsenic trioxide (ATO) is used in the clinic for the treatment of acute promyelocytic leukemia by targeting the protein PML. However, many zinc-finger proteins could also be reactive to arsenic in cells. Here we found that ATO preferentially binds to the ring-finger domain of PML in a protein mixture with zinc-finger domains. These results provide the molecular basis of the target selection of ATO in cells.
Related Papers
- → Accumulation and Transformation of Arsenic in the Blue-Green Alga Synechocysis sp. PCC6803(2011)94 cited
- → Arsenic Removal and Biotransformation Potential of Exiguobacterium Isolated From an Arsenic‐Rich Soil of Chhattisgarh, India(2015)18 cited
- → Determination of arsenic metabolites in patients with newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide(2013)7 cited
- → Determination of arsenic compounds in human urine by HPLC-ICP-MS(1997)15 cited
- Analysis of Arsenic Metabolites in Patients with Acute Promyelocytic Leukemia Treated with Arsenic Trioxide(2014)